{"id":"bdd-with-udca","safety":{"commonSideEffects":[{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4531991","moleculeType":"Unknown","molecularWeight":"428.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"UDCA is a hydrophilic bile acid that reduces the hydrophobicity of the bile acid pool and protects hepatocytes from cytotoxic bile acids. BDD likely acts as a farnesoid X receptor (FXR) agonist or bile acid receptor modulator to enhance cytoprotective signaling. Together, they reduce cholestasis, hepatic inflammation, and fibrosis progression in cholestatic liver diseases.","oneSentence":"BDD (a bile acid derivative) combined with UDCA (ursodeoxycholic acid) enhances bile acid signaling and reduces hepatic inflammation and cholestasis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:44.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary biliary cholangitis (PBC)"},{"name":"Primary sclerosing cholangitis (PSC) or other cholestatic liver disease"}]},"trialDetails":[{"nctId":"NCT03578055","phase":"PHASE3","title":"BDD With UDCA Therapy After Laparoscopic Cholecystectomy","status":"UNKNOWN","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2018-04-24","conditions":"Cholecystitis, Acute, Cholecystitis, Chronic","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["UDEX"],"phase":"phase_3","status":"active","brandName":"BDD with UDCA","genericName":"BDD with UDCA","companyName":"Ewha Womans University Mokdong Hospital","companyId":"ewha-womans-university-mokdong-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDD (a bile acid derivative) combined with UDCA (ursodeoxycholic acid) enhances bile acid signaling and reduces hepatic inflammation and cholestasis. Used for Primary biliary cholangitis (PBC), Primary sclerosing cholangitis (PSC) or other cholestatic liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}